Benzinga
27 Mar 2026, 14:40 UTC · 25w ago
Verdict
Headline takes no side. We score KOD +1.00 across four claims — strongly bullish.
+1.00strongly bullish
More positive than 98% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Kodiak Sciences announced positive Phase 3 GLOW2 study results for Zenkuda, showing 62.5% of treated patients achieved a two-step improvement in DRSS scores versus 3.3% for sham.
So whatStrong clinical trial efficacy in a Phase 3 study is a primary catalyst for biotech valuation and potential FDA approval.
More positive than 99% of claims this week
Zenkuda reduced the risk of sight-threatening complications by 85%, with only 2.4% of treated patients experiencing events compared to 15.8% in the sham group.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
More positive than 97% of claims this week
Kodiak Sciences intends to accelerate the submission timeline for a multi-indication biologics license application (BLA).
More positive than 92% of claims this week
Zenkuda was reported as well tolerated, with no cases of intraocular inflammation and a low rate of cataract adverse events.
More positive than 77% of claims this week
Which stocks this story touches
More positive than 98% of ticker scores this week
The company reported positive Phase 3 clinical trial results for Zenkuda and is accelerating its BLA submission timeline, leading to a stock price surge.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Business Wire
13h ago
−21.5%
Price is moving against the score
$31.23 vs $39.76 close before publication (Mar 26) · not market-adjusted
KOD chart →
